Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BOLD Audentes Therapeutics (BOLD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrends About Audentes Therapeutics Stock (NASDAQ:BOLD) 30 days 90 days 365 days Advanced Chart Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get Audentes Therapeutics alerts:Sign Up Key Stats Today's Range$2.69▼$2.7750-Day Range$59.97▼$59.9752-Week Range$22.00▼$60.00Volume50,291 shsAverage Volume76,621 shsMarket Capitalization$60.43 millionP/E RatioN/ADividend YieldN/APrice Target$23.00Consensus RatingBuy Company OverviewAudentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.Read More… Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Audentes Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks50th Percentile Overall ScoreBOLD MarketRank™: Audentes Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 564th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAudentes Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAudentes Therapeutics has received no research coverage in the past 90 days.Read more about Audentes Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Audentes Therapeutics are expected to grow in the coming year, from ($3.85) to ($3.72) per share.Price to Book Value per Share RatioAudentes Therapeutics has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Audentes Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.49% of the float of Audentes Therapeutics has been sold short.Short Interest Ratio / Days to CoverAudentes Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Audentes Therapeutics has recently decreased by 20.73%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAudentes Therapeutics does not currently pay a dividend.Dividend GrowthAudentes Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.49% of the float of Audentes Therapeutics has been sold short.Short Interest Ratio / Days to CoverAudentes Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Audentes Therapeutics has recently decreased by 20.73%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 3 people have searched for BOLD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Audentes Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of Audentes Therapeutics is held by insiders.Read more about Audentes Therapeutics' insider trading history. Receive BOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Audentes Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BOLD Stock News HeadlinesBoundless Bio Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 7, 2024 | globenewswire.comBoundless Bio to Participate in the 2024 Guggenheim Global Healthcare ConferenceNovember 5, 2024 | globenewswire.comThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…November 21, 2024 | WealthPress (Ad)Boundless Bio to Participate in the 2024 Cantor Global Healthcare ConferenceSeptember 11, 2024 | globenewswire.comGene therapy firm to close California site, shift projects to $100M Sanford facilitySeptember 7, 2024 | bizjournals.comKim Kardashian's Bold Hair Makeover Is Turning HeadsSeptember 2, 2024 | newsweek.comBoundless Bio Inc. Common StockAugust 21, 2024 | 247wallst.comBoundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial ResultsAugust 12, 2024 | globenewswire.comSee More Headlines BOLD Stock Analysis - Frequently Asked Questions How were Audentes Therapeutics' earnings last quarter? Audentes Therapeutics Inc (NASDAQ:BOLD) posted its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.74) EPS for the quarter, topping analysts' consensus estimates of ($0.76) by $0.02. When did Audentes Therapeutics IPO? Audentes Therapeutics (BOLD) raised $100 million in an initial public offering on Thursday, March 28th 2024. The company issued 6,250,000 shares at $16.00 per share. When did the company's lock-up period expire? Audentes Therapeutics' lock-up period expired on Tuesday, September 24th. Audentes Therapeutics had issued 6,250,000 shares in its public offering on March 28th. The total size of the offering was $100,000,000 based on an initial share price of $16.00. Since the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted. What other stocks do shareholders of Audentes Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Audentes Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alphabet (GOOG) and Visa (V). Company Calendar Last Earnings11/07/2024Today11/21/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/06/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BOLD CUSIPN/A CIK1628738 Webwww.audentestx.com Phone415-818-1001FaxN/AEmployees207Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$25.00 Low Stock Price Target$20.00 Potential Upside/Downside+748.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-321.10% Return on Assets-40.02% Debt Debt-to-Equity RatioN/A Current Ratio17.03 Quick Ratio17.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares22,300,000Free FloatN/AMarket Cap$60.43 million OptionableNo Data BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:BOLD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Audentes Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BOLD Stock Alerts